These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30506404)

  • 1. Evaluation of cytokine profiles in rheumatoid arthritis patients with clinically active disease and normal inflammatory indices.
    Alex AM; Sayles H; Mikuls TR; Kerr GS
    Clin Rheumatol; 2019 Apr; 38(4):1075-1081. PubMed ID: 30506404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values.
    Chung MK; Park B; Kim IJ; Cho SK; Kim D; Sung YK; Choi CB; Choe JY; Chung WT; Hong SJ; Kim TH; Koh E; Lee SS; Yoon BY; Park H; Bae SC; Lee J
    Int J Rheum Dis; 2019 May; 22(5):852-859. PubMed ID: 30677239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre observational study comparing patient reported outcomes to assess reliability of swollen and tender joint assessments and response to certolizumab treatment as compared to clinician assessments in rheumatoid arthritis.
    Inderjeeth CA; Inderjeeth AJ; Raymond WD
    Int J Rheum Dis; 2019 Jan; 22(1):73-80. PubMed ID: 30187688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year.
    Kay J; Morgacheva O; Messing SP; Kremer JM; Greenberg JD; Reed GW; Gravallese EM; Furst DE
    Arthritis Res Ther; 2014 Feb; 16(1):R40. PubMed ID: 24485007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet.
    Bakker MF; Jacobs JW; Kruize AA; van der Veen MJ; van Booma-Frankfort C; Vreugdenhil SA; Bijlsma JW; Lafeber FP; Welsing PM
    Ann Rheum Dis; 2012 Jun; 71(6):830-5. PubMed ID: 22128075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents.
    Pincus T; Richardson B; Strand V; Bergman MJ
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-47-54. PubMed ID: 25365089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(2):e001050. PubMed ID: 31908842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated DAS28-ESR in patients with rheumatoid arthritis who have comorbid fibromyalgia is associated more with tender joint counts than with patient global assessment or swollen joint counts: implications for assessment of inflammatory activity.
    Kannayiram S; Schmukler J; Li T; Goodson N; Sridhar A; Pincus T
    Clin Exp Rheumatol; 2024 May; 42(5):1083-1090. PubMed ID: 38525998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis.
    Mäkinen H; Kautiainen H; Hannonen P; Möttönen T; Korpela M; Leirisalo-Repo M; Luukkainen R; Puolakka K; Karjalainen A; Sokka T
    J Rheumatol; 2007 Oct; 34(10):1987-91. PubMed ID: 17611990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period.
    Glimm AM; Sprenger LI; Haugen IK; Mansmann U; Hermann S; Häupl T; Hoff P; Burmester GR; Backhaus M; Le L; Ohrndorf S
    Arthritis Res Ther; 2019 Sep; 21(1):209. PubMed ID: 31533820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sensitivity to change for lower disease activity is greater than for higher disease activity in rheumatoid arthritis trials.
    Zhang B; Lavalley M; Felson DT
    Ann Rheum Dis; 2009 Aug; 68(8):1255-9. PubMed ID: 18697778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis.
    Baker JF; England BR; George M; Cannon G; Sauer B; Ogdie A; Hamilton BC; Hunter C; Duryee MJ; Thiele G; Mikuls TR
    Ann Rheum Dis; 2021 May; 80(5):566-572. PubMed ID: 33397733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity.
    Arntz OJ; Pieters BCH; Thurlings RM; Wenink MH; van Lent PLEM; Koenders MI; van den Hoogen FHJ; van der Kraan PM; van de Loo FAJ
    Front Immunol; 2018; 9():2388. PubMed ID: 30420853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.
    Lee YC; Hackett J; Frits M; Iannaccone CK; Shadick NA; Weinblatt ME; Segurado OG; Sasso EH
    Rheumatology (Oxford); 2016 Apr; 55(4):640-8. PubMed ID: 26608972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level.
    Riazzoli J; Nilsson JÅ; Teleman A; Petersson IF; Rantapää-Dahlqvist S; Jacobsson LT; van Vollenhoven RF
    Rheumatology (Oxford); 2010 Nov; 49(11):2098-103. PubMed ID: 20615918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up.
    Manivel VA; Mullazehi M; Padyukov L; Westerlind H; Klareskog L; Alfredsson L; Saevarsdottir S; Rönnelid J
    Ann Rheum Dis; 2017 Sep; 76(9):1529-1536. PubMed ID: 28336519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes.
    Gul HL; Eugenio G; Rabin T; Burska A; Parmar R; Wu J; Ponchel F; Emery P
    Rheumatology (Oxford); 2020 Mar; 59(3):613-621. PubMed ID: 31424522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.